257 related articles for article (PubMed ID: 27397590)
1. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.
Zignol M; Dean AS; Alikhanova N; Andres S; Cabibbe AM; Cirillo DM; Dadu A; Dreyer A; Driesen M; Gilpin C; Hasan R; Hasan Z; Hoffner S; Husain A; Hussain A; Ismail N; Kamal M; Mansjö M; Mvusi L; Niemann S; Omar SV; Qadeer E; Rigouts L; Ruesch-Gerdes S; Schito M; Seyfaddinova M; Skrahina A; Tahseen S; Wells WA; Mukadi YD; Kimerling M; Floyd K; Weyer K; Raviglione MC
Lancet Infect Dis; 2016 Oct; 16(10):1185-1192. PubMed ID: 27397590
[TBL] [Abstract][Full Text] [Related]
2. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.
Zignol M; Cabibbe AM; Dean AS; Glaziou P; Alikhanova N; Ama C; Andres S; Barbova A; Borbe-Reyes A; Chin DP; Cirillo DM; Colvin C; Dadu A; Dreyer A; Driesen M; Gilpin C; Hasan R; Hasan Z; Hoffner S; Hussain A; Ismail N; Kamal SMM; Khanzada FM; Kimerling M; Kohl TA; Mansjö M; Miotto P; Mukadi YD; Mvusi L; Niemann S; Omar SV; Rigouts L; Schito M; Sela I; Seyfaddinova M; Skenders G; Skrahina A; Tahseen S; Wells WA; Zhurilo A; Weyer K; Floyd K; Raviglione MC
Lancet Infect Dis; 2018 Jun; 18(6):675-683. PubMed ID: 29574065
[TBL] [Abstract][Full Text] [Related]
3. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
4. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
[TBL] [Abstract][Full Text] [Related]
5. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance.
Alame-Emane AK; Xu P; Pierre-Audigier C; Cadet-Daniel V; Shen X; Sraouia M; Siawaya JF; Takiff H; Gao Q; Gicquel B
Int J Tuberc Lung Dis; 2015 Jun; 19(6):679-84. PubMed ID: 25946359
[TBL] [Abstract][Full Text] [Related]
6. Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia.
Bwalya P; Yamaguchi T; Mulundu G; Nakajima C; Mbulo G; Solo ES; Fukushima Y; Kasakwa K; Suzuki Y
Tuberculosis (Edinb); 2018 Mar; 109():117-122. PubMed ID: 29559115
[TBL] [Abstract][Full Text] [Related]
7. Pyrazinamide Susceptibility and
Rahman A; Ferdous SS; Ahmed S; Rahman SMM; Uddin MKM; Pholwat S; Gratz J; Houpt E; Banu S
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630193
[TBL] [Abstract][Full Text] [Related]
8. Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: pncA sequencing versus Bactec MGIT 960.
Maslov DA; Zaĭchikova MV; Chernousova LN; Shur KV; Bekker OB; Smirnova TG; Larionova EE; Andreevskaya SN; Zhang Y; Danilenko VN
Tuberculosis (Edinb); 2015 Sep; 95(5):608-12. PubMed ID: 26071666
[TBL] [Abstract][Full Text] [Related]
9. Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.
Ngabonziza JCS; Diallo AB; Tagliani E; Diarra B; Kadanga AE; Togo ACG; Thiam A; de Rijk WB; Alagna R; Houeto S; Ba F; Dagnra AY; Ivan E; Affolabi D; Schwoebel V; Trebucq A; de Jong BC; Rigouts L; Daneau G;
PLoS One; 2017; 12(10):e0187211. PubMed ID: 29088294
[TBL] [Abstract][Full Text] [Related]
10. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
[TBL] [Abstract][Full Text] [Related]
11. Pyrazinamide resistance in rifampicin discordant tuberculosis.
Mvelase NR; Singh R; Swe Swe-Han K; Mlisana KP
PLoS One; 2022; 17(9):e0274688. PubMed ID: 36129921
[TBL] [Abstract][Full Text] [Related]
12. A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.
Fofana MO; Shrestha S; Knight GM; Cohen T; White RG; Cobelens F; Dowdy DW
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956422
[TBL] [Abstract][Full Text] [Related]
13. Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.
Tahseen S; Khanzada FM; Rizvi AH; Qadir M; Ghazal A; Baloch AQ; Mustafa T
PLoS One; 2020; 15(9):e0239328. PubMed ID: 32966321
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data.
Dean AS; Zignol M; Cabibbe AM; Falzon D; Glaziou P; Cirillo DM; Köser CU; Gonzalez-Angulo LY; Tosas-Auget O; Ismail N; Tahseen S; Ama MCG; Skrahina A; Alikhanova N; Kamal SMM; Floyd K
PLoS Med; 2020 Jan; 17(1):e1003008. PubMed ID: 31961877
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis.
Whitfield MG; Streicher EM; Dolby T; Simpson JA; Sampson SL; Van Helden PD; Van Rie A; Warren RM
Tuberculosis (Edinb); 2016 Jul; 99():128-130. PubMed ID: 27450014
[TBL] [Abstract][Full Text] [Related]
16. Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen.
Lempens P; Decroo T; Aung KJM; Hossain MA; Rigouts L; Meehan CJ; Van Deun A; de Jong BC
Int J Infect Dis; 2020 Nov; 100():357-365. PubMed ID: 32829049
[TBL] [Abstract][Full Text] [Related]
17. Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment.
Kuo CY; Wang WH; Huang CH; Chen YH; Lu PL
J Microbiol Immunol Infect; 2018 Feb; 51(1):88-93. PubMed ID: 28698044
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda.
Naluyange R; Mboowa G; Komakech K; Semugenze D; Kateete DP; Ssengooba W
PLoS One; 2020; 15(5):e0232543. PubMed ID: 32413052
[TBL] [Abstract][Full Text] [Related]
19. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
[TBL] [Abstract][Full Text] [Related]
20. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
